Cáncer de cabeza y cuello

  1. Olivares, A. 1
  2. Del Barco, E. 1
  3. Bellido, L. 1
  4. Cigarral, B. 1
  5. Claros, J. 1
  6. Escalera, E. 1
  7. Barrios, B. 1
  8. Casado, D. 1
  9. Figuero, L. 1
  10. López, A. 1
  11. Terán, E. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1393-1401

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.004 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El cáncer de cabeza y cuello (CCC) es una entidad que engloba un conjunto de tumores con origen, diagnóstico, tratamiento y pronóstico similar. Su compleja presentación y manejo requieren de un enfoque multidisciplinar, con una especial atención a su tratamiento y a las secuelas asociadas a los mismos. La estadificación de estos tumores se basa en la clasificación de la AJCC, 8° edición. La toma de una biopsia del tumor primario o de sus metástasis es fundamental en todos los campos. La tomografía por emisión de positrones (PET) es la prueba de referencia para el diagnóstico en estadios no metastásicos. La radioterapia (RT) y la cirugía tienen resultados similares en tumores localizados. Los tumores localmente avanzados deben dividirse en resecables (preferencia a la cirugía) o irresecables (estándar con quimioterapia —QT— y RT concomitante). Los tumores metastásicos constan de una primera línea de tratamiento con inmunoterapia con o sin QT, habiendo en segunda línea múltiples fármacos con actividad antitumoral. La reevaluación periódica con panendoscopia, tomografía computadorizada (TC) y exploración física es el estándar en el seguimiento de estos pacientes.

Referencias bibliográficas

  • Iglesias LC, Arrazubi V, Baste N, Carral A, Cirauqui B, Escobar Y, et al. SEOM clinical guidelines for the treatment of head and neck cáncer (2017). Clin Transl Oncol. 2018; 20(1):75-83.
  • Paleri V, Urbano TG, Mehanna H, Repanos C, Lancaster J, Ro-ques T, et al. Management of neck metastases in head and neck cáncer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130Suppl2: S161-9.
  • IARC. Cancer Incidence, Mortality and Prevalence Worldwide GLOBOCAN 2012. Disponible en: http://gco.iarc.fr/
  • Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 popula-tion-based study. Eur J Cancer. 2015;51(15): 2130-43.
  • Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Inciden-ce trends for human papillomavirus-related and unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26:612-9.
  • Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooledanalysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epide-miol Biomarkers Prev. 2009;18:541-50.
  • Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet On-col. 2010;11:781-9.
  • Chang CP, Chang SC, Chuang SC, Berthiller J, Ferro G, Matsuo K, et al. Age at start of using tobacco on the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium (INHANCE). Cancer Epidemiol. 2019;63:101615.
  • Rampias T, Sasaki C, Psyrri A. Molecular mechanisms of HPV induced carcinogenesis in head and neck. Oral Oncol. 2014;50:356-63.
  • Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, et al. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. Front Oncol. 2020;10:600.
  • Konings H, Stappers S, Geens M, De Winter BY, Lamote K, van Meerbeeck JP, et al. A literature review of the potential diagnostic biomarkers of head and neck neoplasms. Front Oncol. 2020;10:1020.
  • Park BJ, Chiosea SI, Grandis JR. Molecular changes in the mul-tistage pathogenesis of head and neck cancer. Cancer Biomark. 2010; 9:325-39.
  • Ghasemi F, Prokopec SD, MacNeil D, Mundi N, Gameiro SF, Howlett C, et al. Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status. JCI Insight. 2019;4(1): e123443.
  • Martín-Hernán F, Sánchez-Hernández JG, Cano J, Campo J, del Romero J. Oral cancer, HPV infection and evidence of sexual trans-mission. Med Oral Patol Oral Cir Bucal. 2013;18(3):e439-44.
  • Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
  • Pai SI, Westra WH. Molecular pathology of head and neck can-cer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4:49-70.
  • El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, et al. World Health Organisation Classification of Head and Neck Tu-mours. Lyon: IARCPress; 2017.
  • Speight PM. Update on oral epithelial dysplasia and progression to cancer. Head NeckPathol. 2007;1:61-6.
  • Woolgar JA, Triantafyllou A. Squamous cell carcinoma and pre-cursor lesions: clinical pathology. Periodontol. 2011;57:51-72.
  • Georgopoulos R, Liu JC. Examination of the patient with head and neck cancer. Surg Oncol Clin N Am. 2015;24:409-21.
  • Miller FR, Hussey D, Beeram M, Eng T, McGuff S, Otto RA. Positron emission tomography in the management of unknown pri-mary head and neckcarcinoma. Arch Otolaryngol Head Neck Surg. 2005;131:626-9.
  • Som PM, Curtin HD, Mancuso AA. An imaging- based classifica-tion for the cervical nodes designed as an adjunct to recent clinica-llybased nodal classifications. Arch Otolaryngol Head Neck Surg. 1999;125:388-96.
  • Tantiwongkosi B, Yu F, Kanard A, Miller FR. Role of 18F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol. 2014;6:177-91.
  • Leoncini E, Vukovic V, Cadoni G, Pastorino R, Arzani D, Bosetti C, et al. Clinical features and prognostic factors in patients with head and neck cancer: Results from a multicentric study. Cancer Epidemiol. 2015;39(3):367-74.
  • Brierley J, Gospodarowicz MK, Wittekind CH, editors. TNM classification of malignant tumours. 8th ed. Oxford, UK; Hoboken, NJ: John Wiley & Sons, Inc.; 2017.
  • Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S): a multicen-tre cohort study. Lancet Oncol. 2016;17:440-51.
  • Nguyen-Tân PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cis-platin for head and neck carcinomas in the Radiation Therapy On-cology Group 0129 Trial: Long-term report of efficacy and toxicity. J Clin Oncol. 2014;32(34):3858-67.
  • Maghami E, Ismaila N, Alvarez A, Chernock R, Duvvuri U, Gei-ger J, et al. Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck cancer: ASCO Guideline. J Clin Oncol. 2020;38(22):2570-96.
  • Pignon JP, Le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1):4-14.
  • Cooper JC, Pajak TF, Forastierre AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl JMed. 2004; 350:1937–44.
  • Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Iri-goyen A, et al. A randomized phase III trial comparing induction che-motherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25(1):216-25.
  • Hitt R, Iglesias L, López-Pousa A, Berrocal-Jaime A, Grau JJ, García-Girón C, et al. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unre-sectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. Clin Transl Oncol. En prensa 2020. https://doi.org/10.1007/s12094-020-02467-8
  • Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecá C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017;28(9):2206-12.
  • Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in pa-tients with N2 or N3 locally advanced head and neck cancer. J Clin On-col. 2014;32(25):2735-43.
  • Skillington S, Kallogjeri D, Lewis JS, Piccirillo JF. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2017;143(3):253-9.
  • Pendleton KP, Grandis JR. Cisplatin-based chemotherapy op-tions for recurrent and/or metastatic squamous cell cancer of the head and neck. Clin Med Insights Ther. 2013;2013(5): doi: 10.4137/CMT.S10409.
  • Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27.
  • Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol. 2019; 99:104460.
  • Mendenhall WM, Hinerman RW, Amdur RJ, Malyapa RS, Lans-ford CD, Werning JW, et al. Postoperative radiotherapy for squa-mous cell carcinoma of the head and neck. Clin Med Res. 2006; 4(3):200-8.
  • Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus che-motherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-50.
  • Merlano M, Benasso M, Corvó R, Rosso R, Vitale V, Blengio F, et al. Five-year update of a randomized trial of alternatin gradiotherapy and chemotherapy compared with radiotherapy alone in treatmen-tof unresectable squamous cell carcinoma of the head and neck. J Nat Cancer Inst. 1996;88:583-9.
  • Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for Squamous-CellCarcino-ma of the Head and Neck. New Engl J Med. 2006;354:567-78.
  • Forastiere AA, Weber RS, Trotti A. Organ preservation for advan-ced larynx cancer: issues and outcomes. J Clin Oncol. 2015;33(29): 3262-8.
  • Posner MR, Hershock DM, Blajman CR, Michiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and Fluorouracil alone or with Doce-taxel in Head and Neck Cancer. N Engl J Med. 2007;357:1705-15.
  • Vermorken JB, Remenar E, Van Herpen C, Degardin M, Stewart JS, Ka-rra R, et al. Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2011;15Suppl:5530.
  • Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rot-tey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-27.
  • Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016-22. doi: 10.1093/annonc/mdr367.
  • Burtness B, Harrington KJ, Greil R, Souliéres D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomi-sed, open-label, phase 3 study. Lancet. 2019;394(10212):1915-28.
  • Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-67.
  • Rapidis A, Sarlis N, Lefebvre JL, Kies M. Docetaxel in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag. 2008;4(5):865-86.
  • Sharma M, Gupta M, Fotedar V, Sharma A. Methotrexate, an at-tractive agent for palliation in head and neck cancers. South Asian J Cancer. 2014;3(4):229.
  • Chang JT, See LC, Liao CT, Chen LH, Leung WM, Chen SW, et al. Early Stage Nasopharyngeal Carcinoma: Radiotherapy Dose and Time Factors in Tumor Control. Jpn J Clin Oncol. 1998;28(3): 207-13.
  • Zhang B, Li MM, Chen WH, Zhao JF, Chen WQ, Dong YH, et al. Association of chemoradiotherapy regimens and survival among pa-tients with nasopharyngeal carcinoma. JAMA Netw Open. 2019; 2(10):e1913619.
  • Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcita-bine and Cisplatin induction chemotherapy in nasopharyngeal carcino-ma. N Engl J Med. 2019;381(12):1124-35.
  • Toumi N, Kridis WB, Mnejja W, Bouzguenda R, Khanfir A, Ghorbel A, et al. TPF induction chemotherapy followed by concurrent chemora-diotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series. Cancer Radiother. 2018;22(3):216-21.
  • Zhang L, Huang Y, Hong S, Yang Y, Gengsheng Y, Jia J, et al. Gemcita-bine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metas-tatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883-92.
Fuente de los datos: Dialnet